secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-06-22T21:53:56+00:00
Accession:  0001628280-26-044747
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience transfers Nasdaq listing to Capital Market after equity deficiency; bid price non-compliance continues
--------------------------------------------------------------------------------

- Nasdaq approved transfer from Global to Capital Market effective June 23, 2026 due to stockholders' equity of $9.0M below $10M requirement.
- Company previously disclosed bid price below $1 for 30 consecutive days; compliance period runs to Sept 14, 2026.
- Ticker symbol remains SKYE; transfer to Capital Market allows lower $3M equity standard.
- Company monitoring bid price and considering options but no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/0001628280-26-044747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/skye-20260618.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-044747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer